Exploiting Tumor Hypoxia for Targeted Immunotherapy

Contact Us | 1-800-343-7475

Webinar: Exploiting Tumor Hypoxia for Targeted Immunotherapy

Now Available On-Demand

Watch the first webinar in
Bio-Techne's Immuno-Oncology Series

Learning Objectives:

The role of hypoxia in mitochondrial dysfunction and T cell exhaustion
Improving response to immune checkpoint blockade by modulating the
cellular response to hypoxia
Engineering of a hypoxia-sensing chimeric antigen receptor (CAR) T cell
Selective expression of CAR within tumor limits non-specific activation of
CAR T cells targeting a ubiquitously expressed protein

While immune-based therapies have been approved for treatment of hematological malignancies, such as Acute Lymphocytic Leukemia (ALL), Chronic Lymphocytic Leukemia (CLL), and Non-Hodgkin Lymphoma (NHL), solid tumors have proven more challenging. One critical factor in this ongoing search for effective immunotherapy is the dynamic landscape of the tumor microenvironment (TME). Hypoxia is a common feature of the TME, as tumor growth often outpaces the blood supply. It is well established that hypoxic conditions contribute both to tumor metastasis and immunosuppression.

In this webinar, you will learn more about the complex relationship between hypoxia in the TME and immunotherapy. First, Dr. Greg M. Delgoffe will discuss how hypoxia driven metabolic changes in T cells can lead to T cell exhaustion and modulation of hypoxia can improve response to checkpoint blockade.
Then, Dr. James Arnold will share a strategy to improve cellular immunotherapy by exploiting the hypoxic TME.

Speakers

Greg M. Delgoffe, Ph.D.
Associate Professor, Department of Immunology,
University of Pittsburgh

Member, Cancer Immunology and Immunology and Immunotherapy Program, UPMC Hillman Cancer Center

Dr. Delgoffe received his PhD from the Johns Hopkins School of Medicine and performed postdoctoral research at St. Jude Children’s Research Hospital. Research in the Delgoffe lab focuses on the role of metabolism in T cell fate and function, with a particular focus on the nutrient-restricted environment of cancer. Dr. Delgoffe seeks to uncover the metabolic pathways that drive T cell dysfunction within tumors and develop novel strategies to remodel the metabolic landscape of the tumor microenvironment to empower immune cells for anti-cancer function.

		James Arnold, Ph.D. Reader, School of Cancer and Pharmaceutical Sciences, King’s College London Leader, Tumor Immunology Group
Dr. Arnold received his PhD from Oxford University and completed his postdoctoral research at University of Cambridge. Research in the Arnold lab is focused on mechanisms of immunosuppression within the tumor microenvironment and improving cancer immunotherapy.

Bio-Techne Immuno-Onocology Webinar Series 2022

Explore the complexities of the tumor microenvironment, giving insight into the latest discoveries and novel technologies aiding next-generation immunotherapies.

Look for invites to register for the upcoming webinars where you'll be able to ask our speakers the hard-hitting questions about the latest in Immuno-Oncology research, and learn more about this exciting field of cancer research.

Month	Webinar Name	Speaker
March 2022	Exploiting Tumor Hypoxia for Targeted Immunotherapy	Dr. Greg M. Delgoffe & Dr. James Arnold
April 2022	Spatial organization of multicellular immune hubs in MMRd and MMRp colorectal cancer - Register Here	Dr. Jon Chen, MD
May 2022	Title coming soon!	TBA
June 2022	Title coming soon!	TBA

Cancer cell and T cells changing color as they undergo increasing levels of hypoxia, illustrated by red oxygen molecules.

First Name:

Last Name

Work Email Address:

Institution Name:

Research Area:

Country:

State:

Postal Code:

Job Role:

utm_campaign:

utm_medium:

utm_source:

utm_content:

utm_term:

About Us Brands Search for Products Contact

Terms and conditions of Sale | Privacy Policy